Provided are three-dimensional pancreatic organoids derived from the pancreas of a genetically mutated mouse, a method for producing the three-dimensional pancreatic organoids, the use of the three-dimensional pancreatic organoids for drug effect verification and/or drug screening, and a universally applicable standardized drug effect evaluation method/drug screening method.

Provided are methods and materials for assaying known and candidate therapeutics for inotropic cardiac effects in one or more in vitro assay formats comprising preloaded cardiac tissues and/or organoids.

Provided herein are methods of culturing a mammalian cell and various methods that utilize these culturing methods. Also provided are multi-well cell culture plates, e.g., for use in perfusion culturing methods.

In some aspects and embodiments, the invention provides methods for making hematopoietic stem cells, including for HSCT. The method comprises providing a cell population comprising hemogenic endothelial (HE) or endothelial cells, and increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and/or GTPase IMAP Family Member 6 (Gimap6) in the HE and/or endothelial cells under conditions sufficient for stimulating formation of HSCs.

Methods and devices are disclosed for processing stromal precursor cells (i.e., cells which can differentiate into connective tissue cells, such as in muscles, ligaments, or tendons) which can be obtained from fatty tissue extracts obtained via liposuction. Normal processing of a liposuction extract involves centrifugation, to concentrate the stromal cells into a semi-concentrated form called “spun fat”. That “spun fat” can then be treated by mechanical processing (such as pressure-driven extrusion through 0.5 mm holes) under conditions which can gently pry the stromal cells away from extra-cellular collagen fibers and other debris in the “spun fat”. The extruded mixture is then centrifuged again, to separate a highly-enriched population of stromal cells which is suited for injection back into the patient (along with platelet cells, if desired, to further promote tissue repair or regeneration).

Systems and methods for scalable manufacturing of therapeutic cells in bioreactors are disclosed. Fluid dynamic considerations for scale in accordance with an implementation include a method of production of therapeutic cells grown on microcarriers or as cell aggregates in a suspension-based bioreactor includes depositing a suspension comprising cells suspended in a volume of culture fluid into a bioreactor and setting an agitation rate of a mixer disposed in the bioreactor. The method includes actuating the mixer at the set agitation rate to mix the suspension in the bioreactor. The suspension includes a plurality of turbulent eddies generated by the mixer. A magnitude of an energy dissipation rate (EDR) of at least approximately 60% of the turbulent eddies can be less than approximately 0.0015 m2/s3.

The present invention provides an isolated cell composition suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 10.sup.6 CD8+ T cells specific for target peptide antigen(s). In various embodiments, the composition is predominately CD8+ T cells, and at least about 20% of T cells in the composition exhibit a central or effector memory phenotype, providing for a robust and durable adoptive therapy from a natural T cell repertoire that has undergone natural selection.

The present invention provides methods and systems for enhanced production and/or secretion of extracellular vesicles from at least one three-dimensional porous scaffold having a population of stem cells cultured thereon, utilizing various shear stress conditions on a variety of stem cells.

Disclosed herein are contractile cell constructs, methods for using them to treat disease, and methods for making them.

[Summary]

The present invention relates to the establishment of a cell line having immune tolerance property using an optimal temperature profiling technique under a human body-like environment, and use thereof. Specifically, the present invention relates to a method for preparing trophoblast cells consecutively secreting and expressing HLA-G proteins; a method for preparing stem cells consecutively secreting and expressing HLA-G proteins; stem cells consecutively secreting and expressing HLA-G proteins, prepared by the aforementioned preparation method; a method for preparing a culture medium of stem cells consecutively secreting and expressing HLA-G proteins; a culture medium of stem cells consecutively secreting and expressing HLA-G proteins, prepared by the aforementioned preparation method; and an anti-aging or antioxidant composition comprising the culture medium as an active ingredient.

The novel trophoblast cell line and the stem cell line established in the present invention can exhibit immune tolerance property as they consecutively secret and express HLA-G proteins, and the culture medium of the stem cells contains a large amount of proteins capable of recovering various physiological functions and extracellular vesicles, and thus, the novel cell line or a culture medium thereof can be effectively used in various industries such as medicines and cosmetics.